Skip to main content

Table 2 Time courses of circulating level of EPCs and hematological findings between the two groups of patients

From: Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial

Variable

Group 1 ( n = 71)

Group 2 ( n = 71)

P value

Circulating level of EPCs at 48 hours

 CD31/CD34 (%)

1.69 ± 1.01

1.59 ± 0.91

0.514

 KDR/CD34 (%)

1.34 ± 0.92

1.31 ± 0.76

0.823

Circulating level of EPCs at day 7

 CD31/CD34 (%)

1.35 ± 0.76

1.51 ± 1.12

0.343

 KDR/CD34 (%)

1.26 ± 0.82

1.20 ± 0.73

0.623

Circulating level of EPCs at day 21

 CD31/CD34 (%)

1.64 ± 0.80

2.30 ± 1.53

0.04

 KDR/CD34 (%)

1.23 ± 0.73

1.78 ± 1.26

0.004

RBC count (× 106/ml) on day 21

4.49 ± 0.72

4.47 ± 0.70

0.839

Hemoglobin (g/dl) on day 21

13.39 ± 1.73

13.52 ± 1.85

0.693

Hematocrit (%) on day 21

40.12 ± 4.88

40.54 ± 5.22

0.661

WBC count (× 103/ml) on day 21

7.36 ± 2.41

7.09 ± 3.14

0.272

  1. Data are expressed as mean ± standard deviation of patients. Group 1, without erythropoietin treatment; Group 2, with erythropoietin treatment. EPC, endothelial progenitor cell; RBC, red blood cell; WBC, white blood cell.
Back to article page

Critical Care

ISSN: 1364-8535